Alzheimer's disease (AD) is the fourth major cause of mortality in the elderly in the US and the leading cause of dementia worldwide. While pharmacological targets have been discovered, there are no true disease-modifying therapies. We have recently discovered that multiple low-dose infusions of human umbilical cord blood cells (HUCBCs) ameliorate cognitive impairments and reduce Ab-associated neuropathology in PSAPP transgenic mice. However, the mechanism for these effects of HUCBCs remains unclear. In the present study, we examined whether monocytes, as important components of HUCBCs, would have beneficial outcomes on the reduction of AD-like pathology and associated cognitive impairments in PSAPP transgenic AD model mice. PSAPP mice and their wild-type littermates were treated monthly with an infusion of peripheral human umbilical cord blood cell (HUCBC)-derived monocytes over a period of 2 and 4 months, followed by behavioral evaluations, biochemical, and histological analyses. The principal findings of the present study confirmed that monocytes derived from HUCBCs (CB-M) play a central role in HUCBC-mediated cognition-enhancing and Ab pathology-ameliorating activities. Most importantly, we found that compared with CB-M, aged monocytes showed an ineffective phagocytosis of Ab, while exogenous soluble amyloid precursor protein a (sAPPa) could reverse this deficiency. Pretreating monocytes with sAPPa upregulates Ab internalization. Our further studies suggested that sAPPa could form a heterodimer with Abs, with the APP 672-688 (Ab 1-16 ) region being responsible for this effect. This in turn promoted binding of these heterodimers to monocyte scavenger receptors and thus promoted enhanced Ab clearance. In summary, our findings suggest an interesting hypothesis that peripheral monocytes contribute to Ab clearance through heterodimerization of sAPPa with Ab. Further, declined or impaired sAPPa production, or reduced heterodimerization with Ab, would cause a deficiency in Ab clearance and thus accelerate the pathogenesis of AD.
INTRODUCTION
Currently, 26 million people worldwide suffer from Alzheimer's disease (AD). Indeed, it is predicted that the number of AD cases will quadruple and reach worldwide epidemic proportions by 2050. Amyloid-b (Ab) plaques, resulting from defective removal or upregulated buildup, are a central manifestation of AD (39) . It has been proposed that mechanisms involved in Ab clearance might be the key to providing insights into therapeutic interventions. The binding of Ab to receptors that can mediate its clearance has therefore been a major therapeutic focus (10, 24, 35, 41, 43) . Additionally, there is a possibility that the amyloid precursor protein (APP) metabolite, soluble amyloid precursor protein a (sAPPa), may bind to Ab, and this may confer beneficial 2238 DARLINGTON ET AL. effects for the treatment of AD via increasing its clearance from the brain parenchyma (2, 11) .
Although recent advances in cellular and molecular targets have yielded strategies for enhancing Ab clearance and reversing AD-associated Ab deposition, a cure remains elusive. We previously reported human umbilical cord blood cells (HUCBCs) modulated inflammation, diminished Ab pathology, and reduced behavioral deficits in PSAPP (APPswe/PS1dE9) transgenic mice (9) . In the present study, we attempt to determine which mononuclear cell (MNC) population was conferring these effects. Accumulated AD research has suggested that monocytes among MNCs are contributory to promoting Ab clearance (9, 20, 31, 32) . Therefore, we examined whether monocytes purified from HUCBCs would have beneficial outcomes on the reduction of AD-like pathology and rescue of cognitive impairments in PSAPP transgenic AD mice. PSAPP mice and their wild-type littermates were treated monthly with a peripheral HUCBC-derived monocyte infusion over a period of 2 and 4 months, followed by behavioral evaluations as well as biochemical and histological analyses. The present study extends on the HUCBC AD therapy to (1) examine whether monocytes are responsible for the beneficial effects against AD observed in HUCBC therapeutics and (2) to determine the mechanism by which these salutary effects occur.
MATERIALS AND METHODS

Ethics Statement
All experiments were performed in accordance with the guidelines of the National Institutes of Health, and all animal studies were approved by the University of South Florida (USF) Institutional Animal Care and Use Committee. Animals were humanely cared for during all experiments, and all efforts were made to minimize animal suffering. Animals were anesthetized with isoflourane (50 mg/kg) (Sigma-Aldrich, St. Louis, MO, USA) and euthanized by transcardial perfusion with ice-cold physiological saline containing heparin (10 units/ml) (Sigma-Aldrich). In this study, use of human cord blood cells was involved. Ninetyfive to 98% of mononuclear cells from HUCBCs were provided by Saneron CCEL Therapeutics Inc. (Tampa, FL, USA). Saneron used de-identified HUCBC donations from certified commercial sources.
Animals
PSAPP (APPswe/PS1dE9) mice and their wild-type (WT) littermates were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). PSAPP mice overproduce human Ab 1-40 and Ab 1-42 peptides (APP Swedish mutation with a PS1 deletion in exon 9) and from about 4 months develop progressive cerebral Ab deposits with learning and memory impairment, albeit without neuronal loss (1, 5, 9, 17, 23) . All mice were characterized by PCR genotyping for mutant human APP and presenilin 1 (PS1) transgenes. Thus, all mice used in this study are genetically comparable. Both PSAPP mice and their WT littermates were maintained on a 12-h light/12-h dark cycle at ambient temperature and humidity. All cohorts were housed in the animal facility at the USF, Morsani College of Medicine (Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, FL, USA). Animals were fed standard rodent chow and water ad libitum. For the cord blood-derived monocyte experiments, 5.5-month-old PSAPP mice and WT littermates were used. All cohorts were female, and this served to eliminate the possibility of gender discrepancies among groups. All animals in these experiments were observed in a blinded, randomized approach.
HUCBC Preparation
HUCBCs, comprised of 95-98% mononuclear cells, were obtained using a proprietary density gradient solution (DSS-001) developed by Saneron and GE Healthcare. Our purified HUCBCs were cryopreserved and stored in liquid nitrogen at −210°C. HUCBCs were thawed prior to transplantation, at 37°C for 4 min, washed in 0.05 M phosphate-buffered saline (PBS), quantified and assessed for viability (Cell-Dyn; Abbott Laboratories, Abbott Park, IL, USA and Vi-CELL; Beckman Coulter, Indianapolis, IN, USA), and suspended in PBS to achieve a cell concentration of 2 × 10 5 cells per 100 µl for each infusion.
HUCBC-Derived Monocyte Acquisition
The HUCBC suspension was centrifuged and resuspended in monocyte buffer, containing 0.5% bovine serum albumin (BSA) (Sigma-Aldrich) and 2 mM EDTA (Cell Signaling, Beverly, MA, USA) in PBS. Monocytes were separated via positive selection using the MACS Miltenyi Biotec CD14 + MicroBeads human kit (Miltenyi Biotec Inc., San Diego, CA, USA) (44). CD14 + MicroBeads were added to the cell suspension and incubated for 15 min at 4°C. Cells were washed, resuspended in PBS, and run through a column in a magnetic separator. Cells were allowed to flow into a collection flask, and this comprised the monocyte-deficient cord blood (MD-CB) infused in the cohorts. The column was removed and flushed with buffer to obtain an enriched population of cord blood-derived monocytes (CB-M). Acquired monocyte populations were characterized using flow cytometry. Cell counts and viability were determined as described. Cells were centrifuged, resuspended in PBS twice, and aliquots of 2 × 10 5 cells per 100-µl concentration per mouse were made.
Flow Cytometry Analysis of HUCBC-Derived Monocytes
HUCBC-derived monocytes were stained for identification of the subset monocyte population expressing CD14 + using an anti-CD14 + monoclonal antibody (1 µg/ million cells) (Sigma-Aldrich) and FACS analysis by Accuri C6 Flow Cytometer (BD Biosciences, San Jose, CA, USA). Only monocyte populations composed of >~93% CD14 + cells were used in the study. In addition, further flow cytometry analysis of HUCBC-derived monocytes for membrane surface-associated APP and full-length APP was conducted using an anti-Ab N-terminal monoclonal antibody (6E10, 1:2,000; Covance Research Products, Emeryville, CA, USA) and an anti-APP C-terminal polyclonal antibody (pAb751/770, 1:1,000; Calbiochem, Billerica, MA, USA) according to manufacturer specifications.
Western Blot Analysis for APP Levels
Cell lysates from cultured HUCBCs and HUCBC monocytes were assayed by Western blot (WB) analysis. In brief, cells were cultured then lysed in ice-cold lysis buffer (Cell Signaling) (1 mM Na 3 VO 4 , 150 mM NaCl, 1 mM EDTA, 2.5 mM sodium pyrophosphate, 20 mM Tris pH 7.5, 1 mM EGTA, 1% v/v Triton X-100, 1 mM b-glycerolphosphate, 1 µg/ml leupeptin), plus 1 mM PMSF (Sigma-Aldrich). Inherent proteins were separated using 10% gel, transferred to 0.2-µm nitrocellulose membranes (Bio-Rad, Hercules, CA, USA), and visualized using standard immunoblotting protocol. All antibodies were diluted in 0.05 M Trisbuffered saline (TBS) (Sigma-Aldrich), containing 5% (w/v) nonfat dry milk (Bio-Rad). Membranes were immunoblotted with appropriate primary antibody and then probed using an anti-mouse IgG (1:2,000; Cell Signaling) or an anti-rabbit IgG (1:10,000; Thermo Fisher Scientific, Waltham, MA, USA) secondary antibody conjugated with horseradish peroxidase. Proteins were detected with Super Signal West Femto Maximum Sensitivity Substrate and BIOMAX-MR Film (Thermo Fisher Scientific). Primary antibodies include an anti-APP N-terminal monoclonal antibody (22C11, 1:2,000, EMD Millipore, Temecula, CA, USA), an anti-APP C-terminal polyclonal antibody (pAb751/770, 1:1,000) to evaluate APP expression, an anti-Ab 1-16 monoclonal antibody (6E10, 1:2,000), and an anti-b-actin monoclonal antibody (1:4,000; Sigma-Aldrich).
HUCBC-Derived Monocyte Infusion
Briefly, 23 PSAPP mice and WT littermates were randomly assigned into the following four treatment groups: whole HUCBCs (WCB, n = 6), HUCBC-derived monocytes (CB-M, n = 6), monocyte-deficient HUCBC (MD-CB, n = 6), or PBS (n = 5). With respect to the number of PSAPP and WT mice used in the study, each group, with the exception of the PBS-treated cohorts, comprised n = 3 animals per strain. The PBS-treated group consisted of WT (n = 2) and PSAPP (n = 3). The right tail vein of PSAPP mice or their WT littermates was identified and vasodilated using warm water, and then 2 × 10 5 cells/ 100 µl WCB, CB-M, MD-CB or 100 µL PBS per mouse was delivered via right tail vein injection. The injection was performed four times over 2 months and six times over 4 months. HUCBCs were infused at the end of weeks 1, 3, 5, and 7 for the 2-month treatment and at the end of weeks 1, 3, 5, 7, 9, 11, 13, and 15 for the 6-month treatment. We chose to administer these agents intravenously since it is a readily available approach and shown previously in our laboratory to be effective in reducing AD pathology in mice (9) .
Behavioral Tests
Motor and cognitive evaluations were conducted at the end of the 2-month treatment (7.5 months of age) or at the end of the 4-month treatment (9.5 months of age) using the rotarod test for motor activity, as well as the radial arm water maze (RAWM) test and the visible platform in an open pool test for cognitive ability.
Rotarod Test. For 2 consecutive days, mice underwent rotarod test. Mice were positioned on the rod (diameter 3.6 cm) of the equipment (Rotarod 47650 accelerating model; Ugo Basile, Varese, Italy). The rod was set at 4 rpm, and mice were placed five at a time on the rod. Trial time was 5 min, and the rod steadily accelerated from 4 rpm up to 40 rpm. Mice were evaluated by the amount of time they were able to retain their balance on the rod.
Radial Arm Water Maze Test. All mice received 2 days of 15 swims or trials per day. Each swim culminated either when a visible or a submerged underwater goal was located or after 1 min had elapsed. Briefly, the mouse was dropped into a random start arm (predetermined on a score sheet) and allowed to swim until it located and climbed onto the platform (goal) over a period of 1 min. Errors were recorded as any entry into an incorrect arm or failure to enter any arm for the initial 15 s of the trial. Results were analyzed as number of errors made.
Visible Platform in an Open Pool Swim Test. For verification of whether the animals possessed the skills sufficient to complete the water maze task, we used the visible platform in an open pool swim test. In brief, it was performed in the same pool as the RAWM; however, the triangular wedges were removed, and the pool was left open with a visible platform in an imagined quadrant. Latency to find and ascend the platform was measured (60 s maximum).
Tissue Preparation
Subsequent to neurocognitive evaluations, cohorts were anesthetized with isoflourane and sacrificed at either 7.5 or 9.5 months of age. Hindlimbs (for bone marrow) and 500 µl peripheral blood were initially collected, and the mice were then perfused transcardially with an ice-cold physiological saline. Brains were rapidly isolated, and the left hemispheres were frozen immediately in liquid nitrogen and stored at −80°C. For molecular analysis, the left hemispheres were sonicated in RIPA buffer (Cell Signaling Technology) and centrifuged at 14,000 rpm for 1 h at 4°C. Supernatant was transferred to a new tube for soluble Ab analysis, and the pellet was used for insoluble Ab extraction as described previously (42). The right hemispheres were placed in 4% paraformaldehyde (Sigma-Aldrich) in PBS at 4°C overnight and then transferred to a graded series of sucrose solutions (10%, 20%, and 30%, each at 4°C overnight) for cryostat sectioning. Sequential 25-µm coronal sections were cut, and free-floating sections were then stored at 4°C in 24-well plates containing PBS with 100 mM sodium azide (Sigma-Aldrich).
Immunohistochemical Analysis
Sections were immunohistochemically stained using an anti-Ab 17-26 monoclonal antibody (4G8, 1:200; Covance Research Products) in conjunction with the Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA, USA) coupled with 3,3¢-diaminobenzidine (DAB) (Sigma-Aldrich) substrate. For all the staining, a set of sections without adding primary antibody was used as negative staining control. Ab burden (Ab immunoreactive area) was determined by quantitative image analysis of Ab plaques burden in the retrosplenial cortex (RSC), entorhinal cortex (EC), and hippocampus (H) brain regions of PSAPP mice and their WT littermates for each of the groups treated. Images of five 25-µm sections (150 µm apart) through hippocampus and neocortex (RSC, EC brain regions) were captured, and a threshold optical density was obtained that discriminated staining from background. Quantification of 4G8-positive Ab burden is reported as a percentage of immunolabeled area captured (positive pixels divided by total pixels captured). Quantitative image analysis was performed by a single examiner blinded to sample identities. Data are represented as mean ± SD (n = 4 females).
Enzyme-Linked Immunosorbent Assay
The enzyme-linked immunosorbent assay (ELISA) was performed according to our previous methods (37). Soluble Ab 1-40/42 levels in brain homogenates were analyzed by ELISA using Ab 1-40/42 ELISA kits (Invitrogen, Grand Island, NY, USA) in accordance with the manufacturer's instructions. Data are represented as mean ± SD of Ab 1-40/42 (ng/mg of total protein).
Monocyte Phagocytosis Assay
Monocytes were acquired as described earlier from both HUCBCs and aged human blood cells (from senior adults over 70 years old). These cells were further characterized for cell surface CD14 + and APP biomarkers using flow cytometry analysis. Phagocytosis of Ab was conducted as previously described (52). Briefly, primary HUCBC-derived monocytes (CB-M) and aged human blood cell-derived monocytes (aged BC-M) were incubated with 1 µM FITC-Ab 1-42 for 1 h in the absence or presence of sAPPa (100 ng/ml), scavenger receptor class A ligand (SR-A), or unlabeled Ab (naked Ab 42 ). Both extracellular and cell-associated FITC-Ab 1-42 from cellular supernatants and lysates were quantified using fluorometric analysis to determine mean fluorescence value for each sample as previously described (53). For each condition, relative fold change values were calculated as mean fluorescence value for each sample at 37°C/mean fluorescence value for each sample at 4°C. In all of the conditions, an additional control without cells was carried out to account for nonspecific adherence of Ab to the plastic surface of culture plates, and the mean values were normalized to these controls. Monocytes were then fixed and imaged in independent channels using a confocal microscope equipped with Normarski optics.
Cell Culture and Immunoprecipitation
Chinese hamster ovary (CHO) cells overexpressing either WT human APP (CHO/APPwt) or Swedish mutant APP (APPswe) were donated by Dr. Stefanie Hahn and Dr. Sascha Weggen (University of Heinrich Heine, Düsseldorf, Germany). These cells were cultured for 3 h in 10% FBS in DMEM medium, and then the conditioned media were collected, immunoprecipitated using an anti-Ab 17-26 monoclonal antibody (4G8) (1:1,000 dilution; Covance Research Products) and then analyzed by WB using 22C11 (1:1,000 dilution; EMD Millipore) or 6E10 (1:1,000 dilution; Covance Research Products). Alternatively, the conditioned media were immunoprecipitated with 22C11 and then analyzed by WB using 6E10. For our parallel heterodimerization study, truncated sAPPa peptide was incubated with synthesized Ab 1-42 (Sigma-Aldrich), immunoprecipitated with 4G8, and analyzed by WB using 82E1 (1:1,000 dilution; IBL, Minneapolis MN, USA) or 22C11. In addition, CHO/ APPswe-derived conditioned media were collected, immunoprecipitated with 4G8, and then analyzed by WB using 82E1 or 22C11.
Statistical Analysis
All data were presented as mean ± SEM or mean ± SD and normally distributed. For the RAWM test, the oneway analysis of variance (ANOVA) followed by post hoc LSD test was performed to compare differences between groups. For the rotarod test, data were analyzed by ANOVA followed by post hoc Bonferroni test. For Ab burden as well as both soluble and insoluble Ab 1-40/42 , a t-test for independent samples followed by a post hoc Bonferroni was used to determine the significant difference between each MD-CB-, WCB-, CB-M-, and PBS-treated group. A value of p < 0.05 was considered significant. All analyses were performed using the Statistical Package for the Social Sciences (SPSS), release 18.0 (IBM, Armonk, NY, USA).
RESULTS
Characterization of Purified Human Umbilical Cord Blood-Derived Monocytes
CD14 + monocytes were isolated from HUCBCs using a MACS Miltenyi Biotec CD14 + MicroBeads human kit via positive selection and then characterized by FACS analysis. Prior to enrichment, there was a 13% CD14 + monocyte population ( Fig. 1A, upper panel) , whereas after positive selection the population increased to 95% (Fig. 1A, lower panel) . HUCBC-derived monocytes were further investigated for surface and full-length APP using 6E10 and pAb751/770 antibodies, respectively. Antibody 6E10 recognizes total APP, Ab, and b-CTF, while pAb751/770 antibody specifically recognizes full-length APP. Unfractionated HUCBCs and purified CD14 + monocytes were 48.0% and 93.8% positive for surface APP (Fig. 1B) . Conversely, pAb751/770 antibody detected only 0.98% and 3% full-length APP in unfractionated HUCBCs and purified CD14 + monocytes, respectively, indicating full-length APP may have been truncated (Fig. 1C) . To further confirm these data, HUCBCs and HUCBC-derived monocyte lysates were analyzed by WB analysis, indicating that HUCBC-derived monocytes express dramatically more total APP than the whole HUCBCs. The pAb751/770 antibody did not detect any band in both whole HUCBCs and HUCBC-derived monocyte fractions (Fig. 1D ).
Short-Term (2-Month) Administration of HUCBC-Derived Monocytes Improves Learning, Memory, and Motor Function in PSAPP and WT Mice
To investigate whether HUCBC-derived monocytes could improve locomotive and cognitive function, we administered PBS, whole HUCBCs (WCB), HUCBCderived monocytes (CB-M), or monocyte-deficient HUCBC (MD-CB) intravenously in PSAPP and control (aged-matched WT) mice over a 2-month time period and then subjected them to rotarod and RAWM testing ( Fig. 2A) . Beginning with the block 2 trial, CB-M-and WCB-treated PSAPP mice showed significantly fewer errors in RAWM than PBS and MD-CB-treated PSAPP mice (p < 0.01 vs. PBS-PSAPP mice) ( Fig. 2B) . Likewise, WCB-and CB-M-treated WT mice located the target with significantly fewer errors than PBS-treated WT mice during blocks 3 to 5 and 8 (p < 0.05, p < 0.01 vs. PBS-WT and MD-CB-WT littermates). Interestingly, MD-CB-treated PSAPP mice were cognitively inflexible, and MD-CBtreated WT mice learned less at blocks 6 and 7 when compared to their PBS-treated WT littermates (Fig. 2B) . Notably, increased latency to fall over time appeared standard for all mice, while CB-M-treated PSAPP and WT mice displayed overall greater latency to fall. This signified that CB-M-treated PSAPP and WT mice developed enhanced coordination and balance abilities over PBStreated PSAPP and WT mice.
Long-Term (4-Month) Administration of HUCBC-Derived Monocytes Improves Learning, Memory, and Motor Function in PSAPP and WT Mice
To investigate whether long-term (4-month) monocyte administration improves learning, memory, and motor functions, we administered PBS, whole HUCBCs (WCB), Figure 2 . Short-term (2-month) administration of HUCBC-derived monocytes improves learning, memory, and motor function. Both PSAPP and age-matched WT control mice were tested after short-term systemic administration of monocytes (a). Schematic illustration of HUCBC treatment schedule and testing for cognitive and motor function in PSAPP and WT mice. (b) The cognitive function was presented as numbers of entry arm errors before finding the platform. WCB-and CB-M-treated PSAPP mice showed better behavioral performance than PBS-treated group. In addition, CB-M-treated PSAPP mice showed improve behavioral performance than WCB-treated group. In contrast, MD-CB-treated group showed no cognitive improvement. WT littermates also showed similar tendency at each treatment condition. (c) Motor function was also assessed using rotarod test after treatment. WCB-treated PSAPP mice showed enhance motor activity, reflected as enhanced latency to fall, but not statistically significant compared to PBS-treated group. CB-M-treated PSAPP mice showed significantly improved motor activity compared to MD-CB-treated mice on day 1. Similarly, CB-M-treated WT control mice showed significant improvement in motor activity compared to MD-CB-treated group on both days 1 and 2. All data are presented as mean ± SEM (*p < 0.05; **p < 0.01) and analyzed by one-way analysis of variance (ANOVA) with LSD post hoc test (b), or one-way ANOVA with Bonferroni post hoc test (c).
HUCBC-derived monocytes (CB-M), or monocytedeficient HUCBC (MD-CB) intravenously in PSAPP and control (aged-matched WT) mice over a 4-month time period. The behavioral data at 4 months of each treatment were reminiscent of the 2-month treatment results (Fig. 3A-C) . In the RAWM, CB-M-and WCB-treated PSAPP mice showed significantly fewer errors (blocks 2 to 5 on day 1; blocks 6 to 10 on day 2; p < 0.05 and p < 0.01) than all other groups. CB-M-and WCB-treated WT mice likewise showed significantly fewer errors in blocks 4, 5, and 9 compared to other groups. Surprisingly, PBS-treated WT mice showed better performance than the MD-CB-treated group in blocks 3, 7, 9, and 10 ( Fig.  3B) . These findings were further reinforced using the open pool platform swim test to assess whether animals possessed the motor skills sufficient to complete the water maze tasks. Data indicate both 2-and 4-month CB-M treatment outperformed PBS treatment of PSAPP and WT mice at short-and long-term treatment periods (data not shown). Long-term (4-month) administration of HUCBC-derived monocyte improves learning, memory, and motor function. Both PSAPP and aged-match WT control mice were cognitively tested after long-term monocyte administration. (a) Schematic diagram of HUCBC treatment schedule and behavioral testing in PSAPP and WT mice. (b) Hippocampal-dependent learning and memory function was assessed by RAWM test after treatment completion. The cognitive activity was presented as numbers of entry arm errors before finding the platform. Consistent with the 2-month treatment data, WCB-and CB-M-treated PSAPP mice showed improved cognitive function compared with PBS-treated PSAPP mice. WT littermates also showed similar effects with each treatment paradigm. MD-CB treatment did not show behavioral improvement and even exacerbated the cognitive function of WT mice. (c) Motor activity was assessed using rotarod test after monocyte administration. WCB-or CB-M-treated PSAPP mice significantly improve the motor activity, assessed as latency to fall, compared to PBS-treated group, while MD-CB treatment progressively impaired the motor function of WT control group. All data are shown as the mean ± SEM (*p < 0.05; **p < 0.01) and analyzed by one-way analysis of variance (ANOVA) with LSD post hoc test (b), or one-way ANOVA with Bonferroni post hoc test (c).
Rotarod data show that WCB-and CB-M-treated PSAPP and WT mice displayed superior coordination and advanced to the point of sustaining their position on the rod for the entire trial time of 5 min ( Fig. 3C; day 2) compared to both PBS-treated PSAPP and WT groups (p < 0.05, p < 0.01 vs. PBS-PSAPP or WT mice).
HUCBC-Derived Monocytes Markedly Reduce Aβ Deposits
To investigate whether HUCBC-derived monocytes could reduce amyloid pathology, the brains of each mouse were investigated after four different treatments (i.e., PBS, whole HUCBCs (WCB), HUCBC-derived monocytes (CB-M), or monocyte-deficient HUCBC (MD-CB) treatments). WCB-and CB-M-treated PSAPP mice showed reduced amyloid plaques in hippocampal (H), retrosplenial cortex (RSC), and entorhinal (EC) regions compared with PBS-and MD-CB-treated mice using 4G8 immunohistochemical staining (Fig. 4A ). Quantitative image analysis shows that percentage of plaques in the H region in CB-M-and WCB-treated groups was significantly less than PBS-and MD-CB groups (Fig. 4B, upper panel, mean ± SD, n = 4).
In addition, brain homogenates from the 4-month treatment groups were measured for both soluble Ab 1-40 and Ab 1-42 levels by ELISA. WCB-and CB-M-treated PSAPP mice showed significantly decreased levels of both soluble Ab 1-40 and Ab 1-42 compared to PBS and A t-test for independent samples reveals significant differences between HUCBC or HUCBC-derived monocyte (CB-M) treatment and PBS control groups (**p < 0.01), but no significant difference between whole HUCBC (WCB) and CB-M treatment groups (p > 0.05).
MD-CB-treated group (Fig. 4C, middle and lower panels, mean ± SD, n = 4). The 2-month treatment resulted in similar outcomes (data not shown).
Ab Phagocytosis by Aged and Cord Blood Cell-Derived Monocytes
Since phagocytosis by monocytes may be a possible pathway for Ab clearance from the brain (14,31), we hypothesized that HUCBC-derived monocytes might phagocytose Ab. HUCBC-derived monocytes (CB-M) and aged human blood cell-derived monocytes (aged BC-M) were cultured with FITC-Ab 1-42 for 1 h in the presence or absence of sAPPa (100 ng/ml), scavenger receptor class A ligand (SR-A ligand) or unlabeled Ab 1-42 (naked Ab 1-42 ). Extracellular (Fig 5A, upper panel) and cell-associated (lower panel) FITC-Ab 1-42 was then measured from supernatants and lysates, respectively, using a fluorimeter. Data are represented as relative mean fluorescence (mean ± SD) for each sample at 37°C divided by mean fluorescence at 4°C (n = 4 for each condition; p < 0.05, p < 0.01, p < 0.001 vs. aged BC-M). Ab internalization was reflected by the level of cell-associated FITC-Ab 1-42 . Interestingly, CB-M internalized Ab much more than aged BC-M, while sAPPa pretreatment (100 ng/ml) enhanced Ab internalization by aged BC-M. Primary monocytes were then fixed and imaged using confocal microscopy equipped with Normarski optics (Fig. 5B) . The merged image showed significant Ab 42 internalization inside the cytoplasm of CB-M as shown by most of the green fluorescence localized inside the cytoplasmic compartment (left upper panel), while aged CB-M showed much less FITC-Ab 1-42 internalization (left lower panel). Treatment of aged CB-M with sAPPa showed a significant increase in Ab 1-42 internalization in the cytoplasm by these cells (right upper panel), while SR-A ligand reduced this effect (right middle panel). As expected, competition by naked Ab 1-42 significantly decreased FITC-Ab 1-42 internalization by CB-M (left middle panel).
In Vitro Heterodimerization sAPPα With Aβ
In this study, we have shown that sAPPa treatment improves Ab phagocytosis by aged blood monocytes. It is known that APP undergoes homodimerization at the cell surface, while sAPPa disrupts this homodimerization by binding with APP, thereby preventing starvation-induced cell death (18). We hypothesized that sAPPa might also form a heterodimer with Ab, which is then internalized inside the monocytes. To prove sAPPa/Ab heterodimerization, 3-h cultured conditioned media of CHO/APPwt or CHO/APPswe cells were immunoprecipitated with anti-Ab 17-27 antibody (4G8), followed by WB detection using either anti-Ab 1-16 antibody (6E10) (Fig. 6A, left panel) or anti-APP N-terminal antibody (22C11) (Fig. 6A, right  panel) . The 22C11 blot showed only the sAPPa band (~100 kDa), while the 6E10 blot showed both Ab (~4 kDa) and sAPPa (~100 kDa). Moreover, immunoprecipitation with 22C11 followed by WB detection using 6E10 showed both Ab (~4 kDa) and sAPPa (~100 kDa) bands (Fig. 6B) . Taken together, these data suggest a possible sAPPa/Ab heterodimerization in the cell culture system.
sAPPα/Aβ Heterodimerization at APP 672-687 (Aβ 1-16 ) Region
To investigate whether APP 672-687 region is responsible for sAPPa/Ab heterodimerization, truncated sAPPa was incubated with synthetic Ab 1-42 ( Fig. 7A) , immunoprecipitated with 4G8, and then analyzed by WB detection using either anti-Ab 1-16 antibody (82E1) (Fig. 7B ) or anti-APP N-terminal antibody (22C11) (Fig. 7C ). In parallel, CHO/APPswe conditioned media received the same treatments as a negative control. Truncated sAPPa incubated with synthetic Ab 1-42 showed two attached bands with the presence of not only Ab 1-42 (~4 kDa, upper band) but also truncated sAPPa (~4 kDa, lower band) ( Fig. 7B) , while CHO/APPswe conditioned media showed only a single band for Ab 1-42 (~4 kDa). In addition, CHO/APPswe conditioned media clearly show one band for sAPPa (~100 kDa), while truncated sAPPa incubated with synthetic Ab 1-42 clearly shows the presence of truncated sAPPa (~4 kDa) in the same blot. The presence of sAPPa was substantiated by 6E10 WB (data not shown).
DISCUSSION
The role of Ab in AD progression has already been established (19, 34) . The toxic function of this peptide in the brain is reported in many studies. However, the brain-specific receptor for this peptide has not yet been characterized. In many studies, it has been shown that scavenger receptors and LRP internalize Ab. Yazawa and colleagues, for example, reported that formyl peptide receptor like-1, a G protein-coupled receptor usually found in monocytes and microglia, interacts with Ab species causing both internalization and inflammation (51). Generally, Ab accumulation in the brain stimulates an influx of microglia, monocytes, and various proinflammatory cytokines adjacent to that area, which causes localized inflammation and chemoattracts many more immune cells to that area. Ab clearance via enzyme-mediated degradation, anti-Ab autoantibodies, receptor-mediated Ab transport across the BBB, or even therapeutic Ab clearance has been encouraging, but not curative (4,27). We have shown that HUCBC mononuclear cells (MNCs) could modulate inflammation and reduce Ab pathology in combination with markedly rescuing cognitive deficits (9, 36) . However, we could not identify the immune cell type or cells that attributed the above beneficial effects.
HUCBC administration has gained positive acceptance over the years in research and clinical settings as a source of hematopoietic stem cells to treat acquired and genetic diseases. HUCBCs have been used successfully to improve outcomes in many diseases, especially in hematological malignancies (6), spinal cord injury (38), traumatic brain injury (29), stroke (7), cardiovascular disease (21,28), and preclinical models of AD (9, 36) . Brunstein et al. (6) summarized a significant report on the use of allogenic umbilical cord blood cells in hematological malignancies especially in acute leukemia patients. The report suggested the use of cord blood cells under certain conditions, especially when a suitable sibling donor or a conventional donor is unavailable. However, the report data were taken from a single institution. Cord blood stem cells were used successfully in one study involving a spinal cord injured rat animal model, showing that infusion of human cord blood cells can reverse behavioral deficits even after 5 days of administration. Exogenous delivered cord blood cells were found around the injured area (38). Intravenous delivery of human cord blood cells after 1 day in a stroke animal model improved behavioral effects, and stem cells were found around the injured area. In this study the animal was immunocompromised with cyclosporine before administration of cells (46). Human umbilical cord blood progenitor cells were also used to treat acute myocardial infarction in a rat model. It was shown that exogenous cells could reduce infarction size significantly (21). Intravenous delivery of HUCBCderived CD133 + cells improves functional recovery by preventing scar thinning and systolic dilation in a rat myocardial infarction model (28). In our lab we have also used HUCBCs in AD mouse models, showing that multiple low-dose infusions of HUCBCs could improve cognitive function and reduce amyloid pathologies (9) .
HUCBCs comprise a population of hematopoietic stem and progenitor cells. HUCBCs consist of 95% to 98% MNCs, which may contribute to the beneficial effects observed in AD. As part of their immune surveillance, monocytes phagocytose dead cells and other cellular debris (40). Therefore, monocytes may be fundamental to developing effective therapies for AD. It has been postulated that monocytes may be instrumental for enhancing Ab clearance (31). We know that resident microglia and perivascular macrophages are responsible for phagocytic clearance of Ab from the brain parenchyma. A very early study in a rat model by Miyake and colleagues in 1984 showed that peripheral monocytes can enter into the brain after birth and can be detected for up to 3 weeks.
They also found that those cells become morphologically changed in brain microenvironment and form ameboidlike microglia (33). Moreover, peripheral monocytes have been reported to infiltrate the brain parenchyma in various disease conditions such as experimental allergic encephalomyelitis (15), trauma (3,26), neurological disease (47), and infection (13, 25, 30) . Recent studies also show trafficking and infiltration of peripheral monocytes into the brain in psychological stress (47) (48) (49) . It has been shown that peripheral inflammation and tumor necrosis-a (TNF-a) signaling also recruit monocytes into the brain from blood (12). Based on the literature review and our previous study (9, 36) , our present study sought to modify our previous HUCBC study in such a way that only the CD14 + monocyte fraction (HUCBC-derived monocytes), isolated from total HUCBCs, would be infused peripherally over shortand long-term periods of time in PSAPP and WT mice.
The findings of this study suggest that peripheral administration of HUCBC-derived monocytes can improve hippocampal-dependent learning, memory, and motor function in transgenic PSAPP mice. Histological and biochemical analyses of brain tissue reveal that both short (2-month)-and long-term (4-month) administration of HUCBC monocytes reduces amyloid pathology as well as soluble and insoluble Ab in the brain. In future studies, we are planning to explore the fate of HUCBC-derived monocytes in animal models.
Confocal microscopy of culture data clearly shows that the phagocytic capacity of aged monocytes decreased significantly and was restored by sAPPa treatment (Fig.  5) , indicating that this protein might have an important therapeutic role in reducing Ab from the brain parenchyma. Furthermore, the lower phagocytic capacity of aged blood monocytes could be explained by significantly less APP surface expression in aged blood monocytes and therefore correspondingly much lower sAPPa secretion than HUCBC-derived monocytes (shown in Fig. 5 ). It has been shown that the SR-A receptor binds with Ab and promotes internalization and clearance (16, 22, 50) . In addition, there is an increase in microglial expression of SR-A surrounding areas of human brain plaques (8).
The most intriguing part of this study was to identify one of the plausible mechanisms involved in Ab phagocytosis by monocytes. Confocal microscopy and immunoprecipitation technique show that sAPPa binds with Ab 42 species at the cell surface, which promote internalization of Ab peptide inside the monocyte's cytoplasm. We hypothesized that heterodimerization of sAPPa/Ab could be a plausible mechanism by which monocytes or peripheral macrophages reduce amyloid burden from brain parenchyma. Our in vitro experiment showed that the APP 672-687 (Ab 1-16 ) region is responsible for sAPPa/Ab heterodimerization. Many researchers have emphasized that the size of Ab aggregates is crucial for internalization. Weltzien et al. found that smaller aggregates internalized efficiently, but larger aggregates usually spend more time on the monocyte's cell surface (45). The physical limit of Ab aggregated mass size needs to be considered for phagocytosis and inflammation aggravation. Future studies will be required to confirm this sAPPa/Ab heterodimerization in vivo as well. In sum, HUCBC monocytes could open a new therapeutic option in AD.
